Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 7:25 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 74 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: ACTH (Acthar) Gel Clear all

Conditions: CNS Sarcoidosis
Interventions: H.P. Acthar Gel; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: Not listed
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Keratoconjunctivitis Sicca
Interventions: repository corticotropin injection; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Multiple Sclerosis
Interventions: repository corticotropin injection, Saline; Drug
Lead sponsor: University at Buffalo; Other
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Proteinuria, Idiopathic Membranous Nephropathy
Interventions: Repository Corticotropin Injection, Placebo; Drug
Lead sponsor: Mallinckrodt; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 14
States / cities: Sacramento, California • Stanford, California • Jacksonville, Florida + 11 more

Conditions: Proliferative Vitreoretinopathy
Interventions: Adrenocorticotropic Hormone; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Sarcoidosis, Pulmonary Sarcoidosis
Interventions: Acthar gel; Drug
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years to 90 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Kidney Diseases
Interventions: H.P. Acthar Gel; Drug
Lead sponsor: Stanford University; Other
Eligibility: 16 Years to 65 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Stanford, California

Conditions: Nephrotic Syndromes
Interventions: Repository corticotrophin; Drug
Lead sponsor: Arizona Kidney Disease and Hypertension Center; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: Acthar Gel, Placebo; Drug
Lead sponsor: Mallinckrodt ARD LLC; Industry
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 22
States / cities: Palo Alto, California • Fort Collins, Colorado • Bradenton, Florida + 19 more

Conditions: Proteinuria, Transplant Glomerulopathy
Interventions: Acthar; Drug
Lead sponsor: University of Illinois at Chicago; Other
Eligibility: 18 Years to 80 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Multiple Sclerosis
Interventions: Adrenocorticotropic hormone (ACTH) gel (H.P. Acthar®); Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Lupus Nephritis
Interventions: CellCept, ACTHar gel; Drug
Lead sponsor: Columbia University; Other
Eligibility: 16 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Psoriatic Arthritis
Interventions: ACTHar; Drug
Lead sponsor: IRIS Research and Development, LLC; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Plantation, Florida

Conditions: Uveitis
Interventions: Acthar; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Sarcoidosis, Hypercalcemia Due to Sarcoidosis
Interventions: ACTHAR Gel (adrenocorticotropic hormone); Drug
Lead sponsor: Albany Medical College; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 1
States / cities: Albany, New York

Conditions: Ocular Sarcoidosis, Panuveitis, Anterior Uveitis
Interventions: Repository Corticotropin Injection, Repository Corticotropin Injection -Treatment Extension; Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years to 99 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Optic Neuritis
Interventions: ACTHAR; Drug
Lead sponsor: Neuro-Ophthalmologic Associates, PC; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Lupus Erythematosus Systemic Exacerbation
Interventions: H.P. Acthar Gel; Drug
Lead sponsor: Fiechtner, Justus J., M.D., P.C.; Individual
Eligibility: 18 Years to 75 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Lansing, Michigan

Conditions: Fibrillary Glomerulonephritis
Interventions: Acthar Gel 80 UNT/ML Injectable Solution; Drug
Lead sponsor: NephroNet, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 5
States / cities: Stanford, California • Aurora, Colorado • Lawrenceville, Georgia + 2 more

Conditions: Diabetic Nephropathy
Interventions: Repository Corticotropin Injection, Placebo; Drug
Lead sponsor: Mallinckrodt; Industry
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 10
States / cities: Roseville, California • Cooper City, Florida • Miami Springs, Florida + 7 more

Conditions: Multiple Sclerosis
Interventions: Methylprednisolone, ACTH, IV placebo, IM placebo; Drug · Other
Lead sponsor: Neurologique Foundation, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Ponte Vedra, Florida

Conditions: Renal Disease
Interventions: Acthar 80 UNT/ML Injectable Solution, Oral Tab Tacrolimus; Drug
Lead sponsor: NephroNet, Inc.; Other
Eligibility: 65 Years and older · Male only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Lawrenceville, Georgia

Conditions: Treatment Resistant Nephrotic Syndrome
Interventions: ACTHAR gel; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: New York, New York

Conditions: Sarcoidosis, Cutaneous Sarcoidosis
Interventions: ACTHAR Gel 40 units twice weekly, ACTHAR Gel 80 units twice weekly.; Drug
Lead sponsor: Albany Medical College; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Albany, New York

Search by objective public record fields.

Treatment of CNS Sarcoidosis With H.P. Acthar Gel

Repository Corticotropin Injection in Keratoconjunctivitis Sicca

Effect of Adrenocorticotropin Injection With Weekly Interferon Beta in Patients With Relapsing Remitting Multiple Sclerosis (MS)

Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients

Adrenocorticotropic Hormone (ACTH) for Post-op Inflammation in Proliferative Vitreoretinopathy (PVR)

Acthar Gel for Chronic Pulmonary Sarcoidosis (ACPS)

Idiopathic Focal Segmental Glomerulosclerosis (FSGS) and Treatment With ACTH

Prospective Study Evaluating the Effect of Repository Corticotropin in the Treatment of Various Nephrotic Syndromes

Acthar Gel for Multiple Sclerosis That Keeps Getting Better and Worse (RRMS)

Acthar as Rescue Therapy for Transplant Glomerulopathy in Kidney Transplant Recipients

Adrenocorticotropic Hormone (ACTH) Effects on Myelination in Subjects With MS

ACTHar in the Treatment of Lupus Nephritis

Clinical Impact of Acthar in the Psoriatic Arthritis Patient (CLIPS)

Open Label Study of Acthar SQ Gel Injection in Patients With Active Anterior Uveitis

ACTHAR GEL for Sarcoidosis-Associated Calcium Dysregulation: An Open-label Pilot Study

Ocular Sarcoidosis Open Label Trial of ACTHAR Gel

Defining the Functional and Neuro-Protective Potential of ACTHAR in Acute Optic Neuritis

Open-label Trial of Acthar Gel in Subjects With Moderate to Severe Active Systemic Lupus Erythematosus

A Study of Acthar Gel Alone or With Tacrolimus to Reduce Proteinuria in Fibrillary Glomerulopathy Patients

Acthar for Treatment of Proteinuria in Diabetic Nephropathy Patients

Efficacy Study of Adrenocorticotropin Hormone to Treat Multiple Sclerosis (MS) Relapses After Sub-responding to an Initial 3 Day Course of Intravenous (IV) Methylprednisolone

Comparative and Efficacy Study of ACTHar Gel Alone or in Combination With Tacrolimus in Fibrillary Glomerulopathy

Treatment of Resistant Nephrotic Syndrome With ACTH Gel (ACTHAR)

ACTHAR Gel for Cutaneous Sarcoidosis: An Open Label Trial